1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Saxagliptin + metformin
Trade Name:
Komboglyze
Manufacturer/Distributor:
Bristol-Myers Squibb Canada
www.bmscanada.ca
Classification:
Oral antihyperglycemic agent
DPP-4 inhibitor
Incretin enhancer
ATC Class:
A10BD10 - metformin and saxagliptin
Status:
active
Notice of Compliance (yyyy/mm/dd):
2012/07/09
Date Marketed in Canada (yyyy/mm/dd):
2013/04/25
Presentation:
Tablet: 2.5 mg saxagliptin + 500 mg metformin. DIN: 02389169
Tablet: 2.5 mg saxagliptin + 850 mg metformin. DIN: 02389177
Tablet: 2.5 mg saxagliptin + 1000 mg metformin. DIN: 02389185
Comments:
For use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are
already treated with saxagliptin and metformin or who are inadequately controlled on metformin alone.
It is also indicated for use in combination with premixed or long/intermediate acting insulin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with saxagliptin, metformin and premixed or long/intermediate acting insulin or who are inadequately controlled on metformin and
premixed or long/intermediate acting insulin alone.
Back to:
Drug Product Listings 
